Transformative advances in viral vector manufacturing: Unlocking commercial scalability, consistency, and cost-effectiveness

Image credit: Pharma’s Almanac

As cell and gene therapies (CGTs) progress from rare disease treatments to broader in vivo applications, viral vector manufacturing remains a major bottleneck: complex, inefficient, and prohibitively expensive.

Genezen is addressing these issues through its partnership with 4basebio. Unlike pDNA, which requires a master cell bank and multiple optimization steps, our enzymatic synthesis platform enables rapid, high-fidelity production of linear synthetic DNA without a bacterial backbone.

You can find out more about this partnership in the full Pharma’s Almanac article below.